CIRM Funded Clinical Trials

Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

Disease Area:
CIRM Grant:
Award Value:
Trial Sponsor:
University of California, San Francisco
Trial Stage:
Phase 2
Trial Status:
Targeted Enrollment:
120 ID:


Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs.  As a result, breathing becomes difficult and oxygen cannot get into the body.  ARDS is one of the most serious and lethal consequence of COVID-19. 

This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.


Phase 2B trial 


Test safety and efficacy.

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website